Last reviewed · How we verify
Erythroleukemia, FAB M6
Approved treatments
- Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Erythroleukemia, FAB M6 patent landscape — cliff calendar, originator estates, attackable patents
- Erythroleukemia, FAB M6 treatment landscape brief
- Erythroleukemia, FAB M6 treatment updates RSS
Frequently asked questions about Erythroleukemia, FAB M6
What drugs treat Erythroleukemia, FAB M6?
Tracked treatments include Daunorubicin Hydrochloride, Daunorubicine.
What is the treatment for Erythroleukemia, FAB M6?
Standard treatment for Erythroleukemia, FAB M6 includes Daunorubicin Hydrochloride, Daunorubicine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Erythroleukemia, FAB M6 patent cliff · Erythroleukemia, FAB M6 CI report
- Treatment: Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Treatment: Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing